FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

KANEKO YASUNORI 		2. Issuer Name and Ticker or Trading Symbol

Arcus Biosciences, Inc. [ RCUS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY 		3. Date of Earliest Transaction (MM/DD/YYYY)

3/19/2018
(Street)

HAYWARD, CA 94545
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   3/19/2018     C    505050   (1) A   (2) 505050   I   By Kaneko Capital, LLC  
Common Stock   3/19/2018     C    252524   (1) A   (2) 252524   I   By Kaneko Investments, LLC  
Common Stock   3/19/2018     C    33818   (1) A   (2) 96948   I   By Trust  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Convertible Preferred Stock     (2) 3/19/2018     C         505050      (2)   (2) Common Stock   505050     (2) 0   I   By Kaneko Capital, LLC  
Series B Convertible Preferred Stock     (2) 3/19/2018     C         252524      (2)   (2) Common Stock   252524     (2) 0   I   By Kaneko Investments, LLC  
Series B Convertible Preferred Stock     (2) 3/19/2018     C         31253      (2)   (2) Common Stock   31253     (2) 0   I   By Trust  
Series C Convertible Preferred Stock     (2) 3/19/2018     C         2565      (2)   (2) Common Stock   2565     (2) 0   I   By Trust  

Explanation of Responses:
(1)  The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.
(2)  The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
KANEKO YASUNORI
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
HAYWARD, CA 94545 		X



Signatures
/s/ Scott Paraker, Attorney-in-Fact 3/19/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Arcus Biosciences Charts.
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Arcus Biosciences Charts.